MAPT and Alzheimer disease: Currently available fluid biomarkers include amyloid-β (Aβ)42, alone or in ratio with Aβ40 and phosphorylated tau (e.g., p-tau181, p-tau217 and p-tau231) reflecting core AD-related Aβ and tau pathologies, respectively.